JP7744910B2 - α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 - Google Patents

α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法

Info

Publication number
JP7744910B2
JP7744910B2 JP2022542360A JP2022542360A JP7744910B2 JP 7744910 B2 JP7744910 B2 JP 7744910B2 JP 2022542360 A JP2022542360 A JP 2022542360A JP 2022542360 A JP2022542360 A JP 2022542360A JP 7744910 B2 JP7744910 B2 JP 7744910B2
Authority
JP
Japan
Prior art keywords
peptides
pen
compound
lys
methylbenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022542360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509790A (ja
JP2023509790A5 (enExample
Inventor
スニル クマール グプタ
ニシト バチュラル モディ
シャオリ チェン
デヴィッド ワイ． リウ
ラリー シー． マテアキス
Original Assignee
プロタゴニスト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロタゴニスト セラピューティクス， インコーポレイテッド filed Critical プロタゴニスト セラピューティクス， インコーポレイテッド
Publication of JP2023509790A publication Critical patent/JP2023509790A/ja
Publication of JP2023509790A5 publication Critical patent/JP2023509790A5/ja
Priority to JP2025151922A priority Critical patent/JP2025186365A/ja
Application granted granted Critical
Publication of JP7744910B2 publication Critical patent/JP7744910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2022542360A 2020-01-10 2021-01-08 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 Active JP7744910B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025151922A JP2025186365A (ja) 2020-01-10 2025-09-12 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959854P 2020-01-10 2020-01-10
US62/959,854 2020-01-10
PCT/US2021/012842 WO2021142373A1 (en) 2020-01-10 2021-01-08 METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025151922A Division JP2025186365A (ja) 2020-01-10 2025-09-12 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法

Publications (3)

Publication Number Publication Date
JP2023509790A JP2023509790A (ja) 2023-03-09
JP2023509790A5 JP2023509790A5 (enExample) 2023-12-19
JP7744910B2 true JP7744910B2 (ja) 2025-09-26

Family

ID=76788328

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542360A Active JP7744910B2 (ja) 2020-01-10 2021-01-08 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法
JP2025151922A Pending JP2025186365A (ja) 2020-01-10 2025-09-12 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025151922A Pending JP2025186365A (ja) 2020-01-10 2025-09-12 α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法

Country Status (11)

Country Link
US (1) US20230063321A1 (enExample)
EP (1) EP4093421A4 (enExample)
JP (2) JP7744910B2 (enExample)
KR (1) KR20220125268A (enExample)
AU (1) AU2021205415B2 (enExample)
BR (1) BR112022013628A2 (enExample)
CA (1) CA3166637A1 (enExample)
IL (1) IL294580A (enExample)
MX (1) MX2022008486A (enExample)
PH (1) PH12022551651A1 (enExample)
WO (1) WO2021142373A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
CA2949215C (en) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. .alpha.4.beta.7 integrin thioether peptide antagonists
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
KR20250084325A (ko) * 2023-12-01 2025-06-11 주식회사 쓰리빅스 염증성 장질환 예방 또는 치료용 약학 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533833A (ja) 2012-10-11 2015-11-26 プロタゴニスト セラピューティクス， インコーポレイテッド 新規なα４β７ペプチド二量体拮抗薬
JP2017522362A (ja) 2014-05-16 2017-08-10 プロタゴニスト セラピューティクス， インコーポレイテッド α４β７インテグリンチオエーテルペプチドアンタゴニスト

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013011130A (es) * 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
WO2013078375A2 (en) * 2011-11-23 2013-05-30 Amgen Inc. Administration of alpha4beta7 hetero-dimer-specific antibody
JP2017535527A (ja) * 2014-10-01 2017-11-30 プロタゴニスト セラピューティクス， インコーポレイテッド 新規のα４β７ペプチド単量体及び二量体拮抗薬
KR20200015540A (ko) * 2017-05-10 2020-02-12 인사이클 세라퓨틱스, 인코포레이티드 α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533833A (ja) 2012-10-11 2015-11-26 プロタゴニスト セラピューティクス， インコーポレイテッド 新規なα４β７ペプチド二量体拮抗薬
JP2017522362A (ja) 2014-05-16 2017-08-10 プロタゴニスト セラピューティクス， インコーポレイテッド α４β７インテグリンチオエーテルペプチドアンタゴニスト

Also Published As

Publication number Publication date
WO2021142373A1 (en) 2021-07-15
JP2023509790A (ja) 2023-03-09
AU2021205415A8 (en) 2023-08-10
IL294580A (en) 2022-09-01
US20230063321A1 (en) 2023-03-02
AU2021205415B2 (en) 2026-06-04
KR20220125268A (ko) 2022-09-14
PH12022551651A1 (en) 2023-11-20
CA3166637A1 (en) 2021-07-15
EP4093421A1 (en) 2022-11-30
MX2022008486A (es) 2022-10-13
CN115038457A (zh) 2022-09-09
BR112022013628A2 (pt) 2022-11-22
JP2025186365A (ja) 2025-12-23
EP4093421A4 (en) 2024-01-10
AU2021205415A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP2025186365A (ja) α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法
US20240209026A1 (en) A4b7 thioether peptide dimer antagonists
US11111272B2 (en) α4α7 peptide monomer and dimer antagonists
AU2009225389A1 (en) Methods of treating inflammation
AU2014268316B2 (en) Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
JP2012505160A (ja) 炎症を処置する方法
KR20120105429A (ko) 염증 치료 방법
JP2015527357A (ja) 単一可変ドメインとカモスタットメシル酸塩（ｃｍ）とを含んでなる組成物
JP2005537245A5 (ja) プロテイナーゼ活性化レセプターのアンタゴニストを含む組成物および方法
AU2005216298B2 (en) Compositions and methods for the systemic treatment of arthritis
US20230382998A1 (en) METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTS
WO2021032955A1 (en) Treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250912

R150 Certificate of patent or registration of utility model

Ref document number: 7744910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150